Business Wire

Avilar Therapeutics to Present Scientific Poster on ATACs, a New Class of Degraders for Targeting Extracellular Proteins, at Protein Degradation Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs ...
Business Wire

Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders at Targeted Protein Degradation Summit

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present new preclinical data from its ATAC ...
C&EN

Avilar Therapeutics launches with $60 million to degrade extracellular targets

Avilar Therapeutics is joining the growing targeted degrader crowd. But whereas most companies in that area are advancing small molecules that break down intracellular proteins, Avilar is only the ...
C&EN

Extracellular degrader firm raises $130 million to advance into the clinic

GlycoEra is in the sweet spot, raising $130 million to advance sugar-tagged biologics that can drive the degradation of extracellular targets. A first program targeting immunoglobulin G4 (IgG4) ...
technologynetworks

Targeting Disease-Causing Proteins for Destruction

Scientists at the University of Wisconsin-Madison have developed a way to use a cell's own recycling machinery to destroy disease-causing proteins, a technology that could produce entirely new kinds ...